Agents for attention-deficit hyperactivity disorder - an update

被引:5
作者
Howard, HR [1 ]
机构
[1] Pfizer Inc, PGRD Groton Labs, CNS Discovery Chem, Groton, CT 06340 USA
关键词
attention-deficit hyperactivity disorder (ADHD); dopamine; histamine; nicotine; serotonin; stimulants;
D O I
10.1517/13543776.14.7.983
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Attention-deficit hyperactivity disorder (ADHD) is a psychological disorder affecting children and adolescents, whose symptoms often persist into the adult years, and is often effectively treated with stimulants. Recently, non-stimulant medications that demonstrate better toleration and administration have been studied in clinical settings and some have been approved. Yet, there continues to be strong emphasis in many research groups to find even more efficacious and safer alternatives, especially with substances that function through novel, non-stimulatory mechanisms. A review of the progress achieved during the last 4 years, determined from the publication of patents and patent applications, is presented.
引用
收藏
页码:983 / 1008
页数:26
相关论文
共 301 条
  • [1] ABBOTT LAB, 2003, Patent No. 03076431
  • [2] ABBOTT LABS, 2002, Patent No. 0206223
  • [3] ABBOTT LABS, 2003, Patent No. 03059341
  • [4] ABBOTT LABS, 2002, Patent No. 2002169188
  • [5] ACADIA PHARM INC, 2003, Patent No. 03057698
  • [6] ADIR ET CO, 2000, Patent No. 1038873
  • [7] Selegiline in the treatment of attention deficit hyperactivity disorder in children: a double blind and randomized trial
    Akhondzadeh, S
    Tavakolian, R
    Davari-Ashtiani, R
    Arabgol, F
    Amini, H
    [J]. PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 2003, 27 (05) : 841 - 845
  • [8] AKZO NOBEL NV, 2003, Patent No. 03068220
  • [9] AKZO NOBEL NV, 2002, Patent No. 02102808
  • [10] AM HOME PRODUCTS COR, 2001, Patent No. 0138293